Table 1.
Case reports of de novo AIH following COVID-19.
| Case, COVID-19 severity | Laboratory parameters | Liver histology | Time to AIH diagnosis | Treatment |
|---|---|---|---|---|
| 49 years, male, hospitalised35 | ALT 264 IU/L Bili 1.6 mg/dl IgG 2,260 mg/dl ANA 1/80 |
Not performed | 20 days | Prednisolone + azathioprine (relapsed after discontinuation) |
| 72 years, female, hospitalised35 | ALT 640 IU/L Bili 11.2 mg/dl IgG 4,250 mg/dl SMA+ 1/640 |
Not performed | 2 days | Prednisolone + tacrolimus |
| 54 years, male, mild36 | ALT 1,238 IU/L Bili 25 mg/dl IgG 3,151 mg/dl ANA+ 1:2,560 SMA+ 1:45 |
Portal & lobular inflammation, plasma cell infiltrate, interface hepatitis | 1 month | Prednisolone |
| 60 years, female, mild37 | ALT 1,433 IU/L Bili 11.7 mg/dl IgG 2,775 mg/dl ANA+ 1:320 SMA+ 1:80 |
Lobular lymphoplasmacytic infiltration, interface hepatitis | 0 days | ‘Induction therapy’ + azathioprine |
| 57 years, male, mild38 | ALT 106 IU/L Bili 2.1 mg/dl IgG 4,049 mg/dl SMA+ AMA+ Anti-dsDNA+ |
Not performed | 1 month | No immunosuppression |
| 40 years, female, mild39 | ALT 1,300 IU/L Bili 22 mg/dl IgG 2,190 mg/dl ANA+ |
Portal and lobular inflammation, plasma cell infiltrate | 1 month | Prednisolone |
AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AMA, anti-mitochondrial antibody; ANA, antinuclear antibody; Bili, bilirubin; dsDNA, double-stranded DNA; SMA, smooth muscle antibody.